Skip to main content
. 2021 Nov 9;1(3):411–415. doi: 10.1016/j.jacasi.2021.09.002

Figure 1.

Figure 1

Effects of Tafolecimab on LDL-C Levels

Percentage changes from baseline in LDL-C levels in the (A) phase 1a and (B) phase 1b studies. Error bars indicate standard error (SE). IV = intravenously; LDL-C = low-density lipoprotein cholesterol; Q2W, Q4W, Q6W = every 2, 4, 6 weeks; SC = subcutaneously.